DK3555097T3 - Imidazo[4,5-d]pyrrolo[2,3-b]pyridinforbindelser som inhibitorer af janus-kinaser - Google Patents

Imidazo[4,5-d]pyrrolo[2,3-b]pyridinforbindelser som inhibitorer af janus-kinaser Download PDF

Info

Publication number
DK3555097T3
DK3555097T3 DK17854175.1T DK17854175T DK3555097T3 DK 3555097 T3 DK3555097 T3 DK 3555097T3 DK 17854175 T DK17854175 T DK 17854175T DK 3555097 T3 DK3555097 T3 DK 3555097T3
Authority
DK
Denmark
Prior art keywords
pyrrolo
imidazo
inhibitors
pyridine compounds
janus kinases
Prior art date
Application number
DK17854175.1T
Other languages
English (en)
Inventor
Tatiana Koudriakova
Kevin D Kreutter
Kristi Leonard
Michele C Rizzolio
Russell C Smith
Mark S Tichenor
Aihua Wang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK3555097T3 publication Critical patent/DK3555097T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK17854175.1T 2016-12-16 2017-12-15 Imidazo[4,5-d]pyrrolo[2,3-b]pyridinforbindelser som inhibitorer af janus-kinaser DK3555097T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662435609P 2016-12-16 2016-12-16
US201762592680P 2017-11-30 2017-11-30
US201762596607P 2017-12-08 2017-12-08
PCT/US2017/066744 WO2018112379A1 (en) 2016-12-16 2017-12-15 Small molecule inhibitors of the jak family of kinases

Publications (1)

Publication Number Publication Date
DK3555097T3 true DK3555097T3 (da) 2022-07-25

Family

ID=61692222

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17854175.1T DK3555097T3 (da) 2016-12-16 2017-12-15 Imidazo[4,5-d]pyrrolo[2,3-b]pyridinforbindelser som inhibitorer af janus-kinaser

Country Status (34)

Country Link
US (5) US10294226B2 (da)
EP (2) EP4086256A1 (da)
JP (2) JP7291077B2 (da)
KR (1) KR102352462B1 (da)
CN (1) CN110088105B (da)
AU (3) AU2017377069B2 (da)
BR (1) BR112019011968A2 (da)
CA (1) CA3046965A1 (da)
CL (1) CL2019001626A1 (da)
CO (1) CO2019006200A2 (da)
CR (1) CR20190282A (da)
DK (1) DK3555097T3 (da)
EC (1) ECSP19042688A (da)
ES (1) ES2922379T3 (da)
HR (1) HRP20220885T1 (da)
HU (1) HUE059274T2 (da)
IL (1) IL267275B (da)
JO (1) JOP20190143B1 (da)
LT (1) LT3555097T (da)
MD (1) MD3555097T2 (da)
MX (2) MX2019007073A (da)
MY (1) MY196260A (da)
NI (1) NI201900060A (da)
PE (1) PE20191105A1 (da)
PH (1) PH12019501254A1 (da)
PL (1) PL3555097T3 (da)
PT (1) PT3555097T (da)
RS (1) RS63500B1 (da)
SA (1) SA519402216B1 (da)
SI (1) SI3555097T1 (da)
TW (1) TWI777997B (da)
UA (1) UA125042C2 (da)
WO (1) WO2018112379A1 (da)
ZA (1) ZA201904615B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201903182XA (en) 2016-10-24 2019-05-30 Astrazeneca Ab 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ.ベー. Jakファミリーのキナーゼの低分子阻害物質
JOP20190144A1 (ar) * 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
LT3494116T (lt) 2017-01-30 2020-01-10 Astrazeneca Ab Estrogeno receptorių moduliatoriai
JP2021527650A (ja) 2018-06-15 2021-10-14 リアタ ファーマシューティカルズ インコーポレイテッド IL−17およびRORγの阻害用のピラゾール化合物およびイミダゾール化合物
TW202016110A (zh) * 2018-06-15 2020-05-01 比利時商健生藥品公司 Jak激酶家族之小分子抑制劑
WO2020216936A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor
KR20220016955A (ko) * 2019-06-06 2022-02-10 하이라이트ll 파머슈티컬 (하이난) 컴퍼니, 리미티드 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태
CN110483514B (zh) * 2019-09-16 2022-06-14 启元生物(杭州)有限公司 一种氰基取代的环肼衍生物及其应用
AU2021222686B2 (en) * 2020-02-21 2023-06-29 Zhuhai United Laboratories Co., Ltd. Crystalline form of JAK inhibitor and application thereof
CN114149428B (zh) * 2020-09-08 2023-06-13 中国药科大学 吡啶并环类化合物及其制备方法、中间体、组合物和应用
KR20230156752A (ko) 2021-03-11 2023-11-14 얀센 파마슈티카 엔브이 Jak 매개 장애의 치료에 사용하기 위한 로르푸시티닙
CN113292561A (zh) * 2021-05-22 2021-08-24 中国药科大学 一种二吡咯并吡啶结构的化合物、制备方法和医药用途
CN114432317A (zh) * 2021-05-31 2022-05-06 广州嘉越医药科技有限公司 吡咯并嘧啶类化合物的用途
CN113861194B (zh) * 2021-11-10 2022-07-05 英维沃化工科技(广州)有限公司 一种含吡咯并吡啶双酰胺咪唑类化合物及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
EP2251341A1 (en) * 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
CA2615291A1 (en) * 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
CN102118968A (zh) 2008-06-10 2011-07-06 雅培制药有限公司 新的三环化合物
JP2011066747A (ja) * 2009-09-18 2011-03-31 Panasonic Corp 弾性波フィルタ
WO2011068899A1 (en) 2009-12-01 2011-06-09 Abbott Laboratories Novel tricyclic compounds
KR20170118230A (ko) 2009-12-01 2017-10-24 애브비 인코포레이티드 신규한 트리사이클릭 화합물
CN102712640A (zh) * 2010-01-12 2012-10-03 弗·哈夫曼-拉罗切有限公司 三环杂环化合物、其组合物和应用方法
CA2789186A1 (en) 2010-02-10 2011-08-18 Genon Biotechnologies Oy Dual activity kinase domains and uses thereof
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
CA2983453A1 (en) 2015-05-28 2016-12-01 Theravance Biopharma R&D Ip, Llc Naphthyridine compounds as jak kinase inhibitors
EP3371332A4 (en) 2015-11-04 2019-04-03 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR TREATING AUTOIMMUNE DISEASES
SG11201903182XA (en) 2016-10-24 2019-05-30 Astrazeneca Ab 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
RS61108B1 (sr) 2016-12-16 2020-12-31 Lilly Co Eli Jedinjenja 7-feniletilamino-4h-pirimido[4,5-d][1,3]oksazin-2-ona kao inhibitori idh1 i idh2 mutanta
EA037318B1 (ru) 2016-12-16 2021-03-11 Пфайзер Инк. Агонисты рецептора glp-1 и их применение
PE20191322A1 (es) 2016-12-16 2019-09-24 Basf Se Compuestos plaguicidas
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
US20190281874A1 (en) 2016-12-16 2019-09-19 Nestec S.A. Oligosaccharides for flavour generation
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ.ベー. Jakファミリーのキナーゼの低分子阻害物質
LT3494116T (lt) 2017-01-30 2020-01-10 Astrazeneca Ab Estrogeno receptorių moduliatoriai
SG11201909710XA (en) 2017-04-21 2019-11-28 Kyn Therapeutics Indole ahr inhibitors and uses thereof
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Jak激酶家族之小分子抑制劑
WO2020216936A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor

Also Published As

Publication number Publication date
US20180170931A1 (en) 2018-06-21
US11059823B2 (en) 2021-07-13
CN110088105B (zh) 2022-03-18
BR112019011968A2 (pt) 2019-11-05
PH12019501254A1 (en) 2020-01-20
JOP20190143A1 (ar) 2019-06-13
AU2022204240B2 (en) 2023-10-05
HUE059274T2 (hu) 2022-11-28
US20190177321A1 (en) 2019-06-13
US20190185474A1 (en) 2019-06-20
ES2922379T3 (es) 2022-09-14
US10364246B2 (en) 2019-07-30
PE20191105A1 (es) 2019-08-23
CA3046965A1 (en) 2018-06-21
IL267275A (en) 2019-08-29
LT3555097T (lt) 2022-08-25
PT3555097T (pt) 2022-09-22
KR102352462B1 (ko) 2022-01-17
AU2017377069A1 (en) 2019-06-20
JP2020502113A (ja) 2020-01-23
US20210340143A1 (en) 2021-11-04
CL2019001626A1 (es) 2019-10-04
ZA201904615B (en) 2021-05-26
EP4086256A1 (en) 2022-11-09
US10487083B2 (en) 2019-11-26
JP2023071709A (ja) 2023-05-23
US20190177322A1 (en) 2019-06-13
EP3555097A1 (en) 2019-10-23
AU2020257068A1 (en) 2020-11-19
AU2017377069B2 (en) 2020-07-23
AU2022204240A1 (en) 2022-07-07
NI201900060A (es) 2020-03-16
JP7291077B2 (ja) 2023-06-14
ECSP19042688A (es) 2019-06-30
PL3555097T3 (pl) 2022-10-17
MX2019007073A (es) 2019-10-15
CO2019006200A2 (es) 2019-06-28
RS63500B1 (sr) 2022-09-30
MD3555097T2 (ro) 2022-12-31
TW201831180A (zh) 2018-09-01
CR20190282A (es) 2019-08-21
HRP20220885T1 (hr) 2022-12-09
KR20190086779A (ko) 2019-07-23
SA519402216B1 (ar) 2022-10-02
JP7493068B2 (ja) 2024-05-30
MY196260A (en) 2023-03-24
SI3555097T1 (sl) 2022-09-30
IL267275B (en) 2021-07-29
US10294226B2 (en) 2019-05-21
EP3555097B1 (en) 2022-06-15
JOP20190143B1 (ar) 2023-09-17
UA125042C2 (uk) 2021-12-29
CN110088105A (zh) 2019-08-02
TWI777997B (zh) 2022-09-21
MX2022004474A (es) 2023-08-15
WO2018112379A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
DK3555097T3 (da) Imidazo[4,5-d]pyrrolo[2,3-b]pyridinforbindelser som inhibitorer af janus-kinaser
DK3523301T3 (da) Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
DK3523302T3 (da) Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
HUS2200003I1 (hu) Pirrolo [2,3-D]pirimidin származékok mint a Janus-kinázok (JAK) inhibitorai
DK3478682T3 (da) [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser
HK1258905A1 (zh) 作為ret激酶抑制劑的取代的吡唑並[1,5-a]吡啶化合物
DK3808749T3 (da) Pyrazolo[1,5-a]pyrimidiner, der er nyttige som inhibitorer af atr-kinase til behandling af kræftsygdomme
DK3134413T3 (da) Substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer
DK3712152T3 (da) 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
DK3371185T3 (da) 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus-kinase-inhibitorer
DK3840832T3 (da) Imidazo[1,2-b]pyridaziner som trk-inhibitorer
MA46690A (fr) Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
DK3679042T3 (da) Imidazo[1,5-A]pyrazin-derivater som PI3Kdelta-inhibitorer